Strategic partnerships are more important than ever in the pharmaceutical and biotechnology sectors. In forging such collaborations, as well as in mergers and acquisitions and financing transactions, the parties ultimately are confronted with the question, “What is this asset worth?” Any approach to valuation must integrate the scientific underpinnings of the technology, its relationship to competing technologies and its evolution in the global framework of regulatory and intellectual property laws.

A pharmaceutical or biotech development typically emanates from basic research that illuminates a biological phenomenon or biochemical system. Advances gleaned from this research mature into an understanding of the nature of the phenomenon or system. From this understanding should emerge a business plan with specific, quantifiable commercialization targets.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]